BofA raised the firm’s price target on Eli Lilly (LLY) to $1,293 from $1,265 and keeps a Buy rating on the shares. Following a “solid” Q4 update, the firm raised its FY26 and out-year revenue forecasts by 2% and 1%-3%, respectively, driven by strength of Zepbound and Mounjaro outside of the U.S. market share gains, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Hims & Hers confirms $49 monthly starting price for Wegovy pill copy
- Eli Lilly falls after Reuters report of $49 monthly weight loss pill
- Hims & Hers to offer copy of Wegovy pill at $49 per month, Reuters reports
- Eli Lilly price target raised to $1,260 from $1,145 at Goldman Sachs
- Eli Lilly price target raised to $1,280 from $1,200 at Wells Fargo